Need a specific person's email?
Browse Emergent BioSolutions's employee directory (about 1.4K employees) and reveal verified emails free.
Emergent BioSolutions's most common email format is First.Last@emergentbiosolutions.com (ex. John.Doe@emergentbiosolutions.com), used for 75% of emergentbiosolutions.com addresses. Emergent BioSolutions uses 12 email patterns across 3 domains: emergentbiosolutions.com, ebsi.com and paxvax.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of emergentbiosolutions.com |
|---|---|---|
| First.Last@emergentbiosolutions.comMost common | John.Doe@emergentbiosolutions.com | |
| LastF@emergentbiosolutions.com | DoeJ@emergentbiosolutions.com | |
| First_Last@emergentbiosolutions.com | John_Doe@emergentbiosolutions.com | |
| First.L@emergentbiosolutions.com | John.D@emergentbiosolutions.com |
| Format | Example | Share of ebsi.com |
|---|---|---|
| LastF@ebsi.comMost common | DoeJ@ebsi.com | |
| FLast@ebsi.com | JDoe@ebsi.com | |
| FirstL@ebsi.com | JohnD@ebsi.com | |
| Last@ebsi.com | Doe@ebsi.com |
| Format | Example | Share of paxvax.com |
|---|---|---|
| FLast@paxvax.comMost common | JDoe@paxvax.com | |
| Last@paxvax.com | Doe@paxvax.com | |
| FirstLast@paxvax.com | JohnDoe@paxvax.com | |
| FirLast@paxvax.com | JohDoe@paxvax.com |
Browse Emergent BioSolutions's employee directory (about 1.4K employees) and reveal verified emails free.
Biotechnology ResearchMaryland, United States1001-5000 Employees
Emergent BioSolutions is a biotechnology research company focused on developing, manufacturing, and delivering protections against public health threats. Based in Gaithersburg, Maryland, the firm has been in operation for more than twenty years, working to prepare for health emergencies rather than merely reacting to them. Its activities encompass creating products and solutions intended to shield people from potential health threats and to support public health preparedness. The company serves government and public health customers, collaborating with health authorities to provide protective products and related manufacturing capabilities. In a recent development, Emergent entered a multi-year agreement with SAB Biotherapeutics to support the process development and manufacturing of SAB-142, the lead program in clinical development for autoimmune type 1 diabetes.
Most common format
First.Last@emergentbiosolutions.com
Example: John.Doe@emergentbiosolutions.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.